Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors
| Autor: | Miguel Brito-Sanfiel, Cristina Abreu, Esteban Pérez-Gutierrez, Gustavo Mora-Navarro, Blanca Cordero-García, Pilar López-Morandeira, Fernando Gomez-Peralta |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Type 2 diabetes Pharmacology Hypoglycemia 03 medical and health sciences 0302 clinical medicine Endocrinology Pharmacotherapy Diabetes mellitus Internal medicine Outcome Assessment Health Care Internal Medicine medicine Humans Hypoglycemic Agents Insulin 030212 general & internal medicine Dipeptidyl peptidase-4 Aged Retrospective Studies Dipeptidyl-Peptidase IV Inhibitors business.industry Drug Substitution Type 2 Diabetes Mellitus General Medicine Middle Aged medicine.disease Metformin Insulin Long-Acting Regimen Diabetes Mellitus Type 2 Drug Therapy Combination Female business |
| Zdroj: | Experimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 126(5) |
| ISSN: | 1439-3646 |
| Popis: | Introduction This study aimed to confirm the usefulness of basal insulin analogue plus oral antidiabetic drugs (OADs) for type 2 diabetes (T2D) patients inadequately controlled with premixed insulin with/without OADs and assess the role of dipeptidyl peptidase-4 (DPP-4) inhibitors within this regimen in clinical practice. Methods Spanish retrospective observational study that included 186 T2D patients with glycosylated hemoglobin (HbA1c) >7% (53 mmol/mol) despite premixed insulin with/without OADs who had been switched to basal insulin analogue plus OADs. Study data describing the situation before the treatment switch and 6 months later was retrospectively retrieved from patients’ medical charts. Results Switching to a basal insulin plus OADs decreased HbA1c (−1.0%, p Conclusions Basal insulin analogue plus OADs may be a useful treatment for type 2 diabetes patients inadequately controlled with premixed insulin. Administering DPP-4 inhibitors within this regimen may contribute to improve patients’ glycemia, with a favorable weight-change profile and without increasing hypoglycemia risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|